Switch theme
Sign up to access all valuation multiples
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
1994
236
LTM Revenue $77.3M
LTM EBITDA $24.4M
$462M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CellaVision has a last 12-month revenue (LTM) of $77.3M and a last 12-month EBITDA of $24.4M.
In the most recent fiscal year, CellaVision achieved revenue of $74.6M and an EBITDA of $22.7M.
CellaVision expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CellaVision valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $77.3M | XXX | $74.6M | XXX | XXX | XXX |
| Gross Profit | $52.8M | XXX | $50.2M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $24.4M | XXX | $22.7M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $20.2M | XXX | $18.3M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $15.9M | XXX | $14.5M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CellaVision's stock price is SEK 194 (or $20).
CellaVision has current market cap of SEK 4.6B (or $478M), and EV of SEK 4.5B (or $462M).
See CellaVision trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $462M | $478M | XXX | XXX | XXX | XXX | $0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CellaVision has market cap of $478M and EV of $462M.
CellaVision's trades at 6.2x EV/Revenue multiple, and 20.4x EV/EBITDA.
Equity research analysts estimate CellaVision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CellaVision has a P/E ratio of 30.1x.
See valuation multiples for CellaVision and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $478M | XXX | $478M | XXX | XXX | XXX |
| EV (current) | $462M | XXX | $462M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 18.9x | XXX | 20.4x | XXX | XXX | XXX |
| EV/EBIT | 22.9x | XXX | 25.2x | XXX | XXX | XXX |
| EV/Gross Profit | 8.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.1x | XXX | 32.9x | XXX | XXX | XXX |
| EV/FCF | 42.3x | XXX | 37.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCellaVision's last 12 month revenue growth is 10%
CellaVision's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
CellaVision's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CellaVision's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CellaVision and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CellaVision acquired XXX companies to date.
Last acquisition by CellaVision was XXXXXXXX, XXXXX XXXXX XXXXXX . CellaVision acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CellaVision founded? | CellaVision was founded in 1994. |
| Where is CellaVision headquartered? | CellaVision is headquartered in Sweden. |
| How many employees does CellaVision have? | As of today, CellaVision has 236 employees. |
| Who is the CEO of CellaVision? | CellaVision's CEO is Dr. Simon Ostergaard, PhD. |
| Is CellaVision publicy listed? | Yes, CellaVision is a public company listed on STO. |
| What is the stock symbol of CellaVision? | CellaVision trades under CEVI ticker. |
| When did CellaVision go public? | CellaVision went public in 2007. |
| Who are competitors of CellaVision? | Similar companies to CellaVision include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of CellaVision? | CellaVision's current market cap is $478M |
| What is the current revenue of CellaVision? | CellaVision's last 12 months revenue is $77.3M. |
| What is the current revenue growth of CellaVision? | CellaVision revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of CellaVision? | Current revenue multiple of CellaVision is 6.0x. |
| Is CellaVision profitable? | Yes, CellaVision is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CellaVision? | CellaVision's last 12 months EBITDA is $24.4M. |
| What is CellaVision's EBITDA margin? | CellaVision's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of CellaVision? | Current EBITDA multiple of CellaVision is 18.9x. |
| What is the current FCF of CellaVision? | CellaVision's last 12 months FCF is $10.9M. |
| What is CellaVision's FCF margin? | CellaVision's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of CellaVision? | Current FCF multiple of CellaVision is 42.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
